Eprinomectin Inhibits

Introduction: Leishmaniasis remains a significant global health challenge, with current therapies often hampered by toxicity, resistance, and high cost. In this study, we investigated the antileishmanial potential of eprinomectin, a veterinary macrocyclic lactone, to address unmet therapeutic needs. Objectives: This study aimed to evaluate the efficacy of eprinomectin against Methods: The antileishmanial activity of eprinomectin was assessed using in vitro and in vivo models. Mechanistic studies included scanning electron microscopy (SEM) to observe morphological changes, transcriptomic profiling to analyze metabolic pathway alterations, and measurements of reactive oxygen species (ROS). Parasite burden and immune responses were further evaluated in infected mice through histopathology and quantitative assays. Results: Eprinomectin exhibited selective activity against Conclusions: Eprinomectin demonstrates multimodal antileishmanial effects primarily through direct parasiticidal mechanisms. Its efficacy in reducing parasite burden and disrupting critical metabolic and cell cycle processes supports its potential as a starting point for antileishmanial drug development. These findings support further investigation into the translational potential of eprinomectin, including combination strategies with existing leishmaniasis treatments.